These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35950941)

  • 1. Controlled attenuation parameter accurately detects liver steatosis in people with HIV.
    Duarte M; Tien P; Ma Y; Noworolski SM; Korn N; Price JC
    AIDS; 2022 Dec; 36(15):2147-2152. PubMed ID: 35950941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults.
    Price JC; Dodge JL; Ma Y; Scherzer R; Korn N; Tillinghast K; Peters MG; Noworolski S; Tien PC
    AIDS; 2017 Sep; 31(15):2119-2125. PubMed ID: 28723710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients.
    Siddiqui MS; Idowu MO; Stromberg K; Sima A; Lee E; Patel S; Ghaus S; Driscoll C; Sterling RK; John B; Bhati CS
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):367-374. PubMed ID: 32272251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population.
    Hu R; Wu B; Wang C; Wu Z; Zhang X; Chen X; Lu G; Yuan K
    Int J Surg; 2024 Apr; 110(4):2044-2054. PubMed ID: 38215263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of controlled attenuation parameter compared with ultrasound for detecting hepatic steatosis in children with severe obesity.
    Runge JH; van Giessen J; Draijer LG; Deurloo EE; Smets AMJB; Benninga MA; Koot BGP; Stoker J
    Eur Radiol; 2021 Mar; 31(3):1588-1596. PubMed ID: 32910234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparative Study of Ultrasound Attenuation Imaging, Controlled Attenuation Parameters, and Magnetic Resonance Spectroscopy for the Detection of Hepatic Steatosis.
    Bao J; Lv Y; Wang K; Wang Q; Chen Y; Dong Y; Zhu Y; Wang W
    J Ultrasound Med; 2023 Jul; 42(7):1481-1489. PubMed ID: 36583414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.
    Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
    United European Gastroenterol J; 2020 Apr; 8(3):321-331. PubMed ID: 32213023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
    Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
    Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
    de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
    Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis?
    Trowell J; Alukal J; Zhang T; Liu L; Maheshwari A; Yoo HY; Thuluvath PJ
    Dig Dis Sci; 2021 Apr; 66(4):1297-1305. PubMed ID: 32337667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.
    Karlas T; Petroff D; Garnov N; Böhm S; Tenckhoff H; Wittekind C; Wiese M; Schiefke I; Linder N; Schaudinn A; Busse H; Kahn T; Mössner J; Berg T; Tröltzsch M; Keim V; Wiegand J
    PLoS One; 2014; 9(3):e91987. PubMed ID: 24637477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.
    Semmler G; Stift J; Scheiner B; Wöran K; Schwabl P; Paternostro R; Bucsics T; Stättermayer AF; Pinter M; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M
    Dig Dis Sci; 2019 Dec; 64(12):3642-3651. PubMed ID: 31209721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
    Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
    Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
    Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
    World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference.
    Wang JH; Ou HY; Yen YH; Chen CH; Lu SN
    Dig Dis Sci; 2020 May; 65(5):1512-1519. PubMed ID: 31617130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant.
    Hong YM; Yoon KT; Cho M; Chu CW; Rhu JH; Yang KH; Lee JW
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):805-810. PubMed ID: 28379854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Accuracy and Optimal Cut-off of Controlled Attenuation Parameter for the Detection of Hepatic Steatosis in Indian Population.
    Kuchay MS; Choudhary NS; Sharma D; Krishan S; Mishra SK; Wasir JS; Singh MK; Saraf N; Dhampalwar S; Sud R
    J Clin Exp Hepatol; 2022; 12(3):893-898. PubMed ID: 35677514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.